Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q1 2026 · 10-Q
Revenue—
Net Income-$69.01M-$69.01MN/M vs Q1 2025 EPS Diluted-$0.74-$0.74no prior Q1 2025 on file Operating Income-$45,641,000N/M Operating Cash Flow-$57,372,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 5, 2026 · 35 d after period end